13^th Euro Breast Cancer and Therapeutics

Dr Indira Poola has completed her Postdoctoral Fellowship from University of Michigan in 1983. She is currently a scientist in Silbiotech, Inc. Her scientific work is on the subject “ Breast Hyperplasia Risk Signature and Breast Cancer ”

Breast Cancer

Dr. Wiseman is Clinical Professor of Medicine at the Division of Medical Oncology, Keck-USC School of Medicine, and previously was Acting Chief of the Division of Oncology/Hematology at White Memorial Medical Center. Dr. Wiseman has been cited in US News Top Doctors yearly since 2002. He brings more than 40 years of academic and clinical experience to BriaCell Therapeutics Corp. As Co-Founder of BriaCell, he is the inventor for most of the Company’s intellectual property and actively participates in its ongoing technology development. As the former Director of the Breast Cancer Basic Research Laboratory at the University of Texas M.D. Anderson Hospital in the 1970s, he was one of the pioneers of the field of cancer vaccine therapeutics. He has written in over 100 peer-reviewed publications and medical textbook chapters.

oncology, tumor immunology, vaccine development, and genetics

Dr. Mohamed Fathy Ragab is a consultant radiologist who has completed his graduation in Zagazig Univeristy, Egypt. He then conducted post-graduate studies in Tanta Univeristy, Egypt. He also completed his clinical fellowship in diagnostic radiology. Dr. Ragab completed his PET/CT training in Imperial College, London, UK in 2010. As a pioneer in Molecular Imaging and PET/CT scanning in Egypt, Dr. Ragab has joined many PET/CT unites of specialized oncology centers; including International Medical Center, Maadi Military Medical complex and Al-Galaa Military Medical Complex; in-addition to his working in Agouza hospital and PET/CT unit of TechnoScan Radiology centers’ chain. His name appears on many articles that were published in both National and International Journals. Currently, he is engaged in research studies about Role of PET/CT and Molecular Imaging in Management of Cancer Patients in collaboration with Banha University, Egypt.

PET/CT and Molecular Imaging in detection, staging and re-staging of Cancer, as well as therapy monitoring and prediction of therapeutic response in Cancer patients.

Gamal EL-Sayed El-Araby Abdelhameed is Vice manager of administration of medical laboratories at Health affairs directorates, Ministry of Health in Egypt. He obtained a PhD in 2014 on “Early detection of Breast Cancer” in Egyptian women and how to make biostatistics for the epidemiology of breast cancer in women in all Egypt . He holds various positions which includes Medical Analysis Specialist, Manager of microbiology lab & Responsible for water treatment units, Researcher, Medical Representative

Pharmacy and medical supply, chemistry and biology, scientific researcher, disaster risk reduction, crisis and conflict prevention, mitigation, resolution and reconciliation

Dr.Ghina Berjawi completed her MD and Diagnostic Radiology residency at the American University of Beirut, Lebanon. She then completed her Clinical Fellowship in Breast Imaging and Intervention at King’s College Hospital, London, and MD Anderson Cancer Center, followed by a Clinical Fellowship in MR and Transvaginal Ultrasound Imaging and Interventional Radiology of the Female Genital Tract at Centre Hospitalier Universitaire de Limoges, France. She is also a Fellow of The Royal College of Radiologists (FRCR), London, since 2009. She is currently an Associate Professor of Clinical Diagnostic Radiology and director of the Mamdouha Sayed Bobst Breast Unit at the American University of Beirut Medical Center. Her name appears on over 40 original articles and abstracts, and she has presented at various national and international conferences

Breast Imaging, Women’s Imaging

Professor Charles Coombes, Professor of Medical Oncology, Imperial College London. He is also Hon Consultant Medical Oncologist, Imperial College Healthcare Trust.From October 2010 Professor Coombes is Director of The Imperial CRUK Cancer Centre. He is also Chair of The Imperial Cancer Research (UK) Centre Steering Committee and Theme leader for Cancer, Imperial College London He is engaged in developing novel methods for prediction of response to endocrine therapy in breast cancer and also carrying out research aimed at understanding the mechanisms of resistance to endocrine therapy and development of novel anti-cancer drugs

molecular signals controlling aberrant growth of breast cancer cells with specific focus on the oestrogen receptor and allied cell signalling pathways